Curcumin effect in patients with type 2 diabetes mellitus and co-existent dislipidemia

Effects of supplementation with curcumin on serum lipid level in patients with type 2 diabetes mellitus and co-existence dislipidemia: A randomized placebo-controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130408012941N2

Enrollment

Registered

2022-02-08

Start date

2022-02-20

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with type 2 diabetes mellitus and co-existence dislipidemia. Type 2 diabetes mellitus with other specified complication

Interventions

Intervention 1: Intervention group: Patients with type 2 diabetes mellitus and co-existence dislipidemia will recieve curcumin 500 mg and piperidin 5mg with standard care for 12 weeks. Intervention 2:

Eligibility

Sex/Gender

All

Age

35 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with with type 2 diabetes mellitus based on FPG= 126 mg/dL, glycated hemoglobin (HbA1C) = 6.5% OR treatment with antidiabetic drugs. Co-existence of dislipidemia Patient consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy and breast feeding Malignancy Chronic liver dysfunction (alt,ast >3 fold more than normal) Kidny dysfunction (cr>2) Chronic inflammatory diseases Acute infection diseases Endocrine diseases Psychology diseases Secondary causes of hypoglycemia Drug use Change the antidiabetic drugs Obstructive billiary and liver diseases History of gallbladder stones

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: before intervention and 12 weeks after intervention. Method of measurement: Lab test on blood sample.;LDL (low-density lipoprotein). Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;Hemoglobin A1C. Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;HDL (High-density lipoprotein). Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;TG (Triglyceride). Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;Total Cholesterol. Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.	—

Measure

Time frame

Fasting blood sugar. Timepoint: before intervention and 12 weeks after intervention. Method of measurement: Lab test on blood sample.;LDL (low-density lipoprotein). Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;Hemoglobin A1C. Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;HDL (High-density lipoprotein). Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;TG (Triglyceride). Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.;Total Cholesterol. Timepoint: before intervention and 12 weeks after. Method of measurement: Lab test on blood sample.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: before intervention and 12 weeks after. Method of measurement: weight and hight mesurment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSolmaz Hasani

Mashhad University of Medical Sciences

HasaniS@mums.ac.ir0098513

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026